| 20.85 0.71 (3.53%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.25 |
1-year : | 31.83 |
| Resists | First : | 23.33 |
Second : | 27.25 |
| Pivot price | 20.31  |
|||
| Supports | First : | 19.96 |
Second : | 17.87 |
| MAs | MA(5) : | 20.01 |
MA(20) : | 20.31 |
| MA(100) : | 22.05 |
MA(250) : | 21.8 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 41.4 |
D(3) : | 36.8 |
| RSI | RSI(14): 52.3 |
|||
| 52-week | High : | 30 | Low : | 13.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ KMTS ] has closed below upper band by 35.8%. Bollinger Bands are 21.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 21.18 - 21.25 | 21.25 - 21.32 |
| Low: | 19.89 - 19.99 | 19.99 - 20.07 |
| Close: | 20.7 - 20.85 | 20.85 - 20.98 |
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
Thu, 04 Jun 2026
Kestra Medical Technologies (KMTS) grants 25,227 RSUs to director - Stock Titan
Thu, 04 Jun 2026
Kestra Medical (KMTS) director Webster receives 75,681 RSU equity grant - Stock Titan
Thu, 04 Jun 2026
Kestra Medical (KMTS) Chief Commercial Officer awarded 25,227 RSUs in equity grant - Stock Titan
Thu, 04 Jun 2026
Kestra Medical (KMTS) CFO receives 25,227 RSUs vesting over three years - Stock Titan
Thu, 04 Jun 2026
[Form 4] KESTRA MEDICAL TECHNOLOGIES, LTD. Insider Trading Activity - Stock Titan
Thu, 09 Apr 2026
Kestra Medical Technologies Named a 2026 USA TODAY Top Workplaces Award Winner - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 58 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 5 (%) |
| Held by Institutions | 102.8 (%) |
| Shares Short | 3,280 (K) |
| Shares Short P.Month | 3,630 (K) |
| EPS | -5.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.94 |
| Profit Margin | -173 % |
| Operating Margin | -141.7 % |
| Return on Assets (ttm) | -36.9 % |
| Return on Equity (ttm) | -92.7 % |
| Qtrly Rev. Growth | 62.7 % |
| Gross Profit (p.s.) | 0.69 |
| Sales Per Share | 1.43 |
| EBITDA (p.s.) | -2.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | -75 (M) |
| PE Ratio | -3.82 |
| PEG Ratio | 0 |
| Price to Book value | 4.22 |
| Price to Sales | 14.53 |
| Price to Cash Flow | -13.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|